Genomic testing in high-grade serous ovarian cancer: current options and future development

被引：0
作者：
Devlin, Michael-John [1 ,2 ]
Miller, Rowan [2 ,3 ,4 ]
机构：
[1] Queen Mary Univ London, Barts Canc Inst, London, England
[2] St Bartholomews Hosp, Dept Med Oncol, London, England
[3] Univ Coll London Hosp, Dept Med Oncol, London, England
[4] Univ Coll London Hosp NHS Fdn Trust, Med Oncol, London NW1 2PG, England
来源：
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER | 2023年 / 33卷 / 03期
关键词：
Medical Oncology; Ovary; Cystadenocarcinoma; Serous; HOMOLOGOUS RECOMBINATION DEFICIENCY; OLAPARIB MAINTENANCE THERAPY; MISMATCH REPAIR DEFICIENCY; REVERSION MUTATIONS; PARP INHIBITORS; DNA-REPAIR; PLATINUM; BRCA; SENSITIVITY; MECHANISM;
D O I：
10.1136/ijgc-2022-003702
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Understanding the genomic complexity of high-grade serous ovarian cancer is now essential in guiding patient management, particularly in the first-line setting. Our knowledge in this area has expanded rapidly in recent years, with biomarkers developing in parallel to agents designed to exploit cancer-associated genetic aberrations. In this review we will take stock of the current landscape of genetic testing and look towards the future with developments that aim to refine personalized treatment paradigms and track treatment resistance in real time.
引用
收藏
页码：358 / 363
页数：6
相关论文
共 50 条
[21]   First-Line Management of Advanced High-Grade Serous Ovarian Cancer [J].
Mahmood, Reem D. ;
Morgan, Robert D. ;
Edmondson, Richard J. ;
Clamp, Andrew R. ;
Jayson, Gordon C. .
CURRENT ONCOLOGY REPORTS, 2020, 22 (06)
[22]   Advances in small molecule maintenance therapies for high-grade serous ovarian cancer [J].
Fischetti, Margherita ;
Di Donato, Violante ;
Palaia, Innocenza ;
Perniola, Giorgia ;
Tomao, Federica ;
Perrone, Chiara ;
Giancotti, Antonella ;
Di Mascio, Daniele ;
Monti, Marco ;
Muzii, Ludovico ;
Benedetti Panici, Pierluigi ;
Bogani, Giorgio .
EXPERT OPINION ON PHARMACOTHERAPY, 2023, 24 (01) :65-72
[23]   Exploiting the Prevalence of Homologous Recombination Deficiencies in High-Grade Serous Ovarian Cancer [J].
Bouberhan, Sara ;
Philp, Lauren ;
Hill, Sarah ;
Al-Alem, Linah F. ;
Rueda, Bo .
CANCERS, 2020, 12 (05)
[24]   Unveiling drug resistance pathways in high-grade serous ovarian cancer(HGSOC): recent advances and future perspectives [J].
Fu, Ruiting ;
Hu, Ruiyue ;
Li, Wenting ;
Lv, Xifang ;
Zhao, Hanwei ;
Li, Fuxia .
FRONTIERS IN IMMUNOLOGY, 2025, 16
[25]   First-Line Management of Advanced High-Grade Serous Ovarian Cancer [J].
Reem D. Mahmood ;
Robert D. Morgan ;
Richard J. Edmondson ;
Andrew R. Clamp ;
Gordon C. Jayson .
Current Oncology Reports, 2020, 22
[26]   Ultrasound characteristics of early-stage high-grade serous ovarian cancer [J].
Suh-Burgmann, Elizabeth ;
Brasic, Natasha ;
Jha, Priyanka ;
Hung, Yun-Yi ;
Goldstein, Ruth B. .
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2021, 225 (04) :409.e1-409.e8
[27]   Evaluation of mitochondrial biogenesis and ROS generation in high-grade serous ovarian cancer [J].
Koc, Zeynep C. ;
Sollars, Vincent E. ;
Zgheib, Nadim Bou ;
Rankin, Gary O. ;
Koc, Emine C. .
FRONTIERS IN ONCOLOGY, 2023, 13
[28]   Discovery of a biomarker candidate for surgical stratification in high-grade serous ovarian cancer [J].
Lu, Haonan ;
Cunnea, Paula ;
Nixon, Katherine ;
Rinne, Natasha ;
Aboagye, Eric O. ;
Fotopoulou, Christina .
BRITISH JOURNAL OF CANCER, 2021, 124 (07) :1286-1293
[29]   PARP inhibitors in platinum-sensitive high-grade serous ovarian cancer [J].
Robert D. Morgan ;
Andrew R. Clamp ;
D. Gareth R. Evans ;
Richard J. Edmondson ;
Gordon C. Jayson .
Cancer Chemotherapy and Pharmacology, 2018, 81 :647-658
[30]   Current strategies for the targeted treatment of high-grade serous epithelial ovarian cancer and relevance of BRCA mutational status [J].
Angiolo Gadducci ;
Valentina Guarneri ;
Fedro Alessandro Peccatori ;
Graziana Ronzino ;
Giuseppa Scandurra ;
Claudio Zamagni ;
Paolo Zola ;
Vanda Salutari .
Journal of Ovarian Research, 12
12345